10 Best Healthcare Penny Stocks to Buy According to Analysts

4. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Stock Price as of June 27: $2.41

Analyst Upside Potential as of June 27: 246.47%

Number of Hedge Fund Holders as of Q1 2025: 20

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 13, Cantor Fitzgerald reiterated its “Overweight” rating and $13.00 price target for Taysha.

According to their research note, three key factors played a key role in the analysts’ decision. First, Cantor Fitzgerald’s representatives met with Taysha’s management team at the International Rett Syndrome Foundation (IRSF) Scientific Meeting. The occasion provided an opportunity for the analysts to fine-tune their outlook for the company.

Secondly, the affirmation was based on recent positive Phase 1/2 clinical data and a regulatory update for TSHA-102. TSHA-102 is an adeno-associated virus (AAV)-based gene therapy in development for Rett syndrome. The data presented at the IRSF meeting was a reprise presentation of previously released results.

Third, Cantor Fitzgerald noted strong positive sentiment among stakeholders. The sentiment analyzed includes that of investors and key opinion leaders regarding Taysha’s developments. However, the analysts were quick to acknowledge that the sentiment was not reflected in the stock’s current market valuation.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company. It develops AAV-based gene therapies for rare monogenic diseases of the central nervous system. Its lead programs include TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy, among others, targeting conditions such as CLN1, CLN7, and Angelman syndrome.